NCT05291910View on ClinicalTrials.gov

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 12, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Inetetamab

Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks

DRUG

Toripalimab

240mg intravenously every 3 weeks

DRUG

Albumin-Bound Paclitaxel

130mg/m2, IV , D1, D8, q3w

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy Of Medical Sciences, Beijing

All Listed Sponsors
lead

Chinese Academy of Medical Sciences

OTHER

NCT05291910 - Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter